FDA Orange Book
Generic for Visken
Visken contains pindolol. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Visken is pindolol. 4 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
Run it in Rivvi
Map Visken and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Visken products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, oral | 10MG | Discontinued | None | 4 | AB |
| tablet, oral | 5MG | Discontinued | None | 4 | AB |
NDA 018285, held by NOVARTIS PHARMACEUTICALS CORP. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic pindolol
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| AUROBINDO PHARMA USA INC | 074019 | AB (A-rated, therapeutically equivalent) | September 3, 1992 | 10MG, 5MG |
| SUN PHARMACEUTICAL INDUSTRIES INC | 074063 | AB (A-rated, therapeutically equivalent) | January 27, 1994 | 10MG, 5MG |
| MPP PHARMA LLC | 205415 | AB (A-rated, therapeutically equivalent) | January 13, 2016 | 10MG, 5MG |
| UNICHEM LABORATORIES LTD | 211712 | AB (A-rated, therapeutically equivalent) | August 1, 2019 | 10MG, 5MG |
Questions
Is there a generic for Visken?
Yes. The generic name for Visken is pindolol. 4 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
What is the generic name for Visken?
The active ingredient in Visken is pindolol, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.